Accelerated biological aging in COVID-19 patients.
Level 3 - non-randomized controlled study
Non-randomized observational cohort study with healthy controls and longitudinal patient follow-up
PubMed 35440567 · doi:10.1038/s41467-022-29801-8
What was done
Blood samples from 232 healthy controls and 413 COVID-19 patients (stratified into non-severe and severe disease) were profiled using EPIC DNA methylation arrays. Epigenetic clocks and telomere length estimators were applied to measure epigenetic age acceleration and telomere attrition across groups, including longitudinal profiling across clinical phases.
What was found
Epigenetic clocks correlated strongly with chronological age (r > 0.8, p < 0.0001). Epigenetic age acceleration and telomere attrition increased sequentially from healthy individuals to non-severe and severe COVID-19 cases. Longitudinal profiling showed that epigenetic aging accumulation was partly reversed at late clinical phases in some patients. Specific effect sizes and numerical differences between clinical groups were not reported in the abstract.
Why it matters
This study links acute SARS-CoV-2 infection severity to measurable markers of biological aging and telomere shortening, providing evidence that viral-induced epigenetic acceleration can be partially reversed during recovery.
Limits
The abstract omits effect sizes, confidence intervals, patient demographics, and follow-up duration. Analyses were limited to peripheral blood DNA methylation, which is susceptible to confounding from shifts in immune cell subsets during active infection.
Cited by
- supports Patients with severe COVID-19 exhibit a significantly more accelerated inflammatory epigenetic clock compared to asymptomatic or mildly symptomatic patients.